The combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc. represents an important strategic transformation that created Aralez, a specialty pharmaceutical company with a compelling growth platform, from which we believe we can drive significant long-term value creation.

Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ and TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients’ lives, while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez’s Global Headquarters is in Ontario, Canada, the US Headquarters is in Princeton, NJ and the Ireland Headquarters is in Dublin, Ireland.

Aralez has a competitive growth platform, and upon formation, in February 2016, raised committed capital of $350 million from a Deerfield Partners-led syndicate, that includes QLT Inc., Broadfin Capital LLC and JW Asset Management, LLC enabling us to potentially accelerate our transformation and execute our growth strategy. It provides a diversified, growing revenue base and a geographic footprint across North America and Europe, with cardiovascular disease and pain management therapies being its therapeutic anchors, led by a management team with a proven track record and history of success.

Our business model is focused on strategic priorities, which aim to grow a diversified business and deliver meaningful products that are capable of delivering sustainable sales growth and that offer financial and competitive advantages. We strive to maintain a lean, nimble and performance-oriented operating model with strong financial discipline that will allow us to build value organically and through acquisitions. A key accelerator to our business strategy involves seizing high potential growth opportunities through aggressive business development and licensing, with the goal of building on our anchor positions in cardiovascular disease and pain management and expanding into other specialty therapeutic areas.